Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Imagion Biosystems Ltd. ( (AU:IBX) ) has shared an announcement.
Imagion Biosystems Ltd. announced significant progress in its MagSense® HER2 breast cancer imaging agent program, with plans to file an Investigational New Drug (IND) application with the FDA in Q4 2025. The company has received positive feedback from the FDA, completed a $3.5M capital raising to fund the IND submission and initiate a Phase 2 clinical trial, and achieved a major milestone in manufacturing the MagSense® imaging agent. Additionally, Imagion has entered a collaboration with Wayne State University to optimize MRI protocols and appointed Dr. Nina Webster as a Non-Executive Director to strengthen its strategic capabilities.
More about Imagion Biosystems Ltd.
Imagion Biosystems Ltd. is a company focused on improving healthcare outcomes through early cancer detection using its proprietary MagSense® imaging technology.
Average Trading Volume: 8,462,737
Technical Sentiment Signal: Sell
Current Market Cap: A$15.45M
See more data about IBX stock on TipRanks’ Stock Analysis page.